An interventional study of Pre-operative stereotactic ablative body radiotherapy in Cancer of Pancreas, sponsored by CCTU- Cancer Theme. Completed at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by CCTU- Cancer Theme · Not applicable, Interventional, and Other
A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.
This is a single-centre, prospective, non-randomised feasibility study. This study will assess whether SABR can safely be given immediately prior to Whipple's resection by assessing the rate of post-operative complications.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's enrollment of 10 is below the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →CCTU- Cancer Theme is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria Stage 1:
Inclusion Criteria Stage 2:
Exclusion Criteria:
Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
Radiation: Pre-operative stereotactic ablative body radiotherapy
Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
The feasibility of delivering pre-operative SABR followed by immediate surgery as determined by rate of post-operative complications at 30 days.
Rate of post-operative complications measured as the number of adverse events reported up to 30 days post surgery
Time frame: Up to 30days post surgery
Measure of surgical resection margin status following pre-operative SABR and immediate surgery
Measure of Resection margin status (R0 complete resection, R1 microscopic residual tumour, R2 macroscopic residual tumour) from the post surgery histopathology report
Time frame: Post surgery
Measure of local control post SABR and surgery
Number of patients with local control from CT scans up to 12months from the start of SABR
Time frame: 1 year
Measure of disease-free survival post SABR and surgery
Number of patients with disease progression from CT scans up to 12months from the start of SABR
Time frame: 1 year
Measure of overall survival post SABR and surgery
Number of deaths up to 12 months from the start of SABR treatment
Time frame: 1 year
Acute and late toxicity of pre-operative SABR: Number of adverse events
Number of adverse events reported up to 12 months from the start of SABR treatment
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CCTU- Cancer Theme